Moderna: can the vaccine business fund its next phase of growth?
FROM THE WIRE · FINANCE.YAHOO.COM
Moderna MRNA reported better-than-expected third-quarter 2026 results at the start of this month, with both earnings and sales beating expectations. The company also raised its full-year 2026 revenue growth guidance to 15-25% year over year, up from its previous expectation of…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe raised revenue guidance contrasts with high future costs, raising investor doubts about financial sustainability.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna reported third-quarter 2026 earnings and sales above expectations.
- 02The company raised its full-year 2026 revenue growth guidance to 15-25%, up from up to 10%.
- 03At its Analyst Day, it outlined cash costs of about $4 billion in 2027, rising to $4.0-$4.5 billion annually through 2030.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Moderna, Inc.203.84 USD+1.40%today +3.58%Neutral BioNTech SE81.71 USD+0.49%today -1.87%Neutral Pfizer Inc.27.71 USD+0.16%today -1.25%Neutral Merck & Co., Inc.132.90 USD+0.09%today -3.54%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets